Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.
Hofste op Bruinink D, Oliva S, Rihova L, Schmitz A, Gilestro M, Te Marvelde J, Kralova R, Høholt H, Broijl A, Johnsen HE, Hajek R, Boccadoro M, Sonneveld P, Omedè P, Van der Velden VHJ.
Hofste op Bruinink D, et al. Among authors: sonneveld p.
Haematologica. 2020 Oct 5;106(5):1496-1499. doi: 10.3324/haematol.2020.267831.
Haematologica. 2020.
PMID: 33054135
Free PMC article.
No abstract available.